SUPPLEMENT

Q1 2020 — Financial disclosures

Q1 2020PDF · 9 pages948 KB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2020
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q20 ........................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q19 ........................4
Table 3: Sales – Current Year and Prior Year by Quarter ...............5
Table 3a: Sales – U.S. / Ex- U.S. 1Q20............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .........................7
Table 4: Other (Income) Expense ....................................................8

-- 1 of 9 --

Sales 	12,057	$ 	10,816	$ 	11%
Costs, Expenses and Other
Cost of sales (1) 3,312 	3,052 	9%
Selling, general and administrative (1) 2,555 	2,425 	5%
Research and development (1) 2,209 	1,931 	14%
Restructuring costs (2) 72 	153 	-53%
Other (income) expense, net (1) 71 	188 	-62%
Income Before Taxes 	3,838 	3,067 	25%
Taxes on Income (1) 619 	205
Net Income 	3,219 	2,862 	12%
Less: Net Loss Attributable to Noncontrolling Interests (1) - 	(53)
Net Income Attributable to Merck & Co., Inc. 	3,219	$ 	2,915	$ 	10%
Earnings per Common Share Assuming Dilution 	1.26	$ 	1.12	$ 	13%
Average Shares Outstanding Assuming Dilution 	2,547 	2,603
Tax Rate (3) 16.1% 	6.7%
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
(3) The effective income tax rate for the first quarter of 2019 reflects a net tax benefit of $360 million related to the settlement
of certain federal income tax matters.
(2) Represents separation and other related costs associated with restructuring activities under the company's formal
restructuring programs.
1Q19	1Q20
GAAP
% Change
(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See
accompanying tables for details.
1

-- 2 of 9 --

. 	.
Sales 	12,057	$ 	10,816	$ 	11,760	$ 	12,397	$ 	11,868	$ 	46,840	$ 	11%
Costs, Expenses and Other
Cost of sales 	3,312 	3,052 	3,401 	3,990 	3,669 	14,112 	9%
Selling, general and administrative 	2,555 	2,425 	2,712 	2,589 	2,888 	10,615 	5%
Research and development 	2,209 	1,931 	2,189 	3,204 	2,548 	9,872 	14%
Restructuring costs 	72 	153 	59 	232 	194 	638 	-53%
Other (income) expense, net 	71 	188 	140 	35 	(223) 	139 	-62%
Income Before Taxes 	3,838 	3,067 	3,259 	2,347 	2,792 	11,464 	25%
Taxes on Income 	619 	205 	615 	440 	428 	1,687
Net Income 	3,219 	2,862 	2,644 	1,907 	2,364 	9,777 	12%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	- 	(53) 	(26) 	6 	7 	(66)
Net Income Attributable to Merck & Co., Inc. 	3,219	$ 	2,915	$ 	2,670	$ 	1,901	$ 	2,357	$ 	9,843	$ 	10%
Earnings per Common Share Assuming Dilution 	1.26	$ 	1.12	$ 	1.03	$ 	0.74	$ 	0.92	$ 	3.81	$ 	13%
Average Shares Outstanding Assuming Dilution 	2,547 	2,603 	2,588 	2,572 	2,559 	2,580
Tax Rate 	16.1% 	6.7% 	18.9% 	18.7% 	15.3% 	14.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
2Q 	3Q 	4Q 	Full Year 	1Q	1Q 	1Q
2020 	2019 	% Change
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 9 --

Cost of sales 	3,312	$ 	296 	68 	364 	2,948	$
Selling, general and administrative 	2,555 	278 	11 	289 	2,266
Research and development 	2,209 	37 	17 	54 	2,155
Restructuring costs 	72 	72 	72 	-
Other (income) expense, net 	71 	(11) 	(11) 	82
Income Before Taxes 	3,838 	(600) 	(168) 	(768) 	4,606
Income Tax Provision (Benefit) 	619 	(158) (3) (7) (3) (165) 	784
Net Income 	3,219 	(442) 	(161) 	(603) 	3,822
Net Income Attributable to Merck & Co., Inc. 	3,219 	(442) 	(161) 	(603) 	3,822
Earnings per Common Share Assuming Dilution 	1.26	$ 	(0.18) 	(0.06) 	(0.24) 	1.50	$
Tax Rate 	16.1% 	17.0%
Only the line items that are affected by non-GAAP adjustments are shown.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included
in selling, general and administrative expenses reflect approximately $165 million of expenses related to the company's planned spin-off of Organon & Co., approximately
$95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amounts included in research and development expenses
primarily reflect expenses related to a net increase in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income)
expense, net primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the
company's formal restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors
to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This
information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FIRST QUARTER 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Adjustment
Subtotal
3

-- 4 of 9 --

Cost of sales 	3,052	$ 	413 	34 	447 	2,605	$
Selling, general and administrative 	2,425 	(1) 	(1) 	2,426
Research and development 	1,931 	(31) 	(31) 	1,962
Restructuring costs 	153 	153 	153 	-
Other (income) expense, net 	188 	167 	167 	21
Income Before Taxes 	3,067 	(548) 	(187) 	(735) 	3,802
Income Tax Provision (Benefit) 	205 	(98) (3) (31) (3) (293) (4) (422) 	627
Net Income 	2,862 	(450) 	(156) 	293 	(313) 	3,175
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (53) 	(53) 	(53) 	-
Net Income Attributable to Merck & Co., Inc. 	2,915 	(397) 	(156) 	293 	(260) 	3,175
Earnings per Common Share Assuming Dilution 	1.12	$ 	(0.15) 	(0.06) 	0.11 	(0.10) 	1.22	$
Tax Rate 	6.7% 	16.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FIRST QUARTER 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in research and
development expenses primarily reflect a reduction in expenses related to a net decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in
other (income) expense, net primarily reflect goodwill impairment charges related to certain businesses in the Healthcare Services segment, partially offset by royalty income related to the
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Includes a $360 million net tax benefit related to the settlement of certain federal income tax matters and a $67 million tax charge related to the finalization of treasury regulations associated
with the 2017 enactment of U.S. tax legislation.
4

-- 5 of 9 --

2020
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) $12,057 	$10,816 	$11,760 	$12,397 	$11,868 	$46,840 	11 	13
PHARMACEUTICAL 	10,655 	9,663 	10,460 	11,095 	10,533 	41,751 	10 	12
Oncology
Keytruda 	3,284 	2,269 	2,634 	3,070 	3,111 	11,084 	45 	46
Alliance Revenue – Lynparza (2) 145 	79 	111 	123 	132 	444 	84 	86
Alliance Revenue – Lenvima (2) 128 	74 	97 	109 	124 	404 	72 	73
Emend 	43 	117 	121 	98 	53 	388 	-63 	-63
Vaccines (3)
Gardasil / Gardasil 9 	1,097 	838 	886 	1,320 	693 	3,737 	31 	33
ProQuad / M-M-R II / Varivax 	435 	496 	675 	623 	481 	2,275 	-12 	-12
Pneumovax 23 	256 	185 	170 	237 	334 	926 	39 	40
RotaTeq 	222 	211 	172 	180 	227 	791 	5 	6
Vaqta 	60 	47 	58 	62 	71 	238 	28 	31
Hospital Acute Care
Bridion 	299 	255 	278 	284 	313 	1,131 	17 	19
Noxafil 	94 	190 	193 	177 	103 	662 	-50 	-49
Invanz 	64 	72 	78 	57 	57 	263 	-10 	-7
Prevymis 	60 	32 	38 	45 	50 	165 	88 	90
Cancidas 	55 	61 	67 	62 	58 	249 	-10 	-8
Primaxin 	51 	59 	71 	77 	67 	273 	-13 	-11
Cubicin 	46 	88 	67 	52 	50 	257 	-48 	-46
Zerbaxa 	37 	26 	27 	35 	32 	121 	40 	42
Immunology
Simponi 	215 	208 	214 	203 	205 	830 	3 	7
Remicade 	88 	123 	98 	101 	89 	411 	-28 	-27
Neuroscience
Belsomra 	79 	67 	76 	80 	83 	306 	18 	18
Virology
Isentress / Isentress HD 	245 	255 	247 	250 	223 	975 	-4 	-2
Zepatier 	55 	114 	108 	83 	66 	370 	-52 	-51
Cardiovascular
Zetia 	145 	140 	156 	147 	146 	590 	3 	4
Vytorin 	53 	97 	76 	57 	54 	285 	-45 	-44
Atozet 	122 	94 	92 	97 	108 	391 	30 	34
Adempas (4) 56 	48 	53 	57 	57 	215 	18 	20
Alliance Revenue - Adempas (5) 53 	42 	51 	50 	60 	204 	26 	26
Diabetes (6)
Januvia 	774 	824 	908 	807 	943 	3,482 	-6 	-5
Janumet 	503 	530 	533 	503 	475 	2,041 	-5 	-3
Women's Health
Implanon / Nexplanon 	195 	199 	183 	199 	206 	787 	-2 	-1
NuvaRing 	63 	219 	240 	241 	179 	879 	-71 	-71
Diversified Brands
Singulair 	155 	191 	160 	152 	195 	698 	-19 	-17
Cozaar / Hyzaar 	102 	103 	109 	116 	113 	442 	-1 	1
Nasonex 	71 	96 	72 	58 	67 	293 	-26 	-25
Arcoxia 	70 	75 	75 	72 	67 	288 	-6 	-4
Follistim AQ 	41 	57 	63 	62 	58 	241 	-28 	-27
Other Pharmaceutical (7) 1,194 	1,082 	1,203 	1,149 	1,183 	4,615 	10 	12
ANIMAL HEALTH 	1,214 	1,025 	1,124 	1,122 	1,122 	4,393 	18 	21
Livestock 	739 	611 	671 	726 	777 	2,784 	21 	24
Companion Animals 	475 	414 	453 	396 	345 	1,609 	15 	17
Other Revenues (8) 188 	128 	176 	180 	213 	696 	47 	33
(6) Total Diabetes sales were $1,353 million in the first quarter of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million for
the first, second, third and fourth quarters of 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous
corporate revenues, including revenue hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $2,155 million in the first quarter of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million
for the first, second, third and fourth quarters of 2019, respectively.
(4) Net product sales in Merck's marketing territories.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
2019 	1Q
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
5

-- 6 of 9 --

1Q 2020 	1Q 2019 	% Change 	1Q 2020 	1Q 2019 	% Change 	1Q 2020 	1Q 2019 	% Change
TOTAL SALES (1) $12,057 	$10,816 	11 	$5,137 	$4,555 	13 	$6,920 	$6,261 	11
PHARMACEUTICAL 	10,655 	9,663 	10 	4,714 	4,215 	12 	5,941 	5,448 	9
Oncology
Keytruda 	3,284 	2,269 	45 	1,906 	1,284 	48 	1,378 	985 	40
Alliance Revenue - Lynparza (2) 145 	79 	84 	85 	50 	68 	60 	29 	111
Alliance Revenue - Lenvima (2) 128 	74 	72 	90 	50 	79 	38 	24 	58
Emend 	43 	117 	-63 	5 	63 	-92 	38 	53 	-29
Vaccines (3)
Gardasil / Gardasil 9 	1,097 	838 	31 	461 	362 	27 	636 	476 	34
ProQuad / M-M-R II / Varivax 	435 	496 	-12 	333 	343 	-3 	102 	153 	-33
Pneumovax 23 	256 	185 	39 	182 	125 	45 	75 	59 	26
RotaTeq 	222 	211 	5 	140 	154 	-9 	82 	57 	44
Vaqta 	60 	47 	28 	30 	29 	5 	30 	18 	63
Hospital Acute Care
Bridion 	299 	255 	17 	143 	119 	20 	157 	136 	15
Noxafil 	94 	190 	-50 	8 	91 	-92 	87 	99 	-12
Invanz 	64 	72 	-10 	6 	14 	-58 	59 	58 	1
Prevymis 	60 	32 	88 	26 	18 	49 	33 	14 	136
Cancidas 	55 	61 	-10 	3 	1 	133 	52 	60 	-13
Primaxin 	51 	59 	-13 	51 	59 	-13
Cubicin 	46 	88 	-48 	15 	42 	-65 	31 	46 	-31
Zerbaxa 	37 	26 	40 	20 	12 	63 	16 	14 	20
Immunology
Simponi 	215 	208 	3 	215 	208 	3
Remicade 	88 	123 	-28 	88 	123 	-28
Neuroscience
Belsomra 	79 	67 	18 	27 	24 	14 	53 	44 	20
Virology
Isentress / Isentress HD 	245 	255 	-4 	75 	108 	-30 	170 	147 	16
Zepatier 	55 	114 	-52 	18 	33 	-46 	37 	81 	-54
Cardiovascular
Zetia 	145 	140 	3 	(2) 	* 	147 	140 	5
Vytorin 	53 	97 	-45 	3 	3 	18 	50 	94 	-47
Atozet 	122 	94 	30 	122 	94 	30
Adempas (4) 56 	48 	18 	56 	48 	18
Alliance Revenue - Adempas (5) 53 	42 	26 	49 	40 	20 	5 	2 	133
Diabetes (6)
Januvia 	774 	824 	-6 	355 	384 	-7 	419 	440 	-5
Janumet 	503 	530 	-5 	113 	167 	-32 	390 	364 	7
Women's Health
Implanon / Nexplanon 	195 	199 	-2 	149 	149 	45 	50 	-10
NuvaRing 	63 	219 	-71 	26 	185 	-86 	37 	34 	8
Diversified Brands
Singulair 	155 	191 	-19 	5 	5 	-11 	151 	186 	-19
Cozaar / Hyzaar 	102 	103 	-1 	7 	4 	78 	95 	99 	-4
Nasonex 	71 	96 	-26 	6 	(1) 	* 	65 	97 	-33
Arcoxia 	70 	75 	-6 	70 	75 	-6
Follistim AQ 	41 	57 	-28 	21 	29 	-30 	21 	28 	-25
Other Pharmaceutical (7) 1,194 	1,082 	10 	409 	328 	25 	780 	754 	3
ANIMAL HEALTH 	1,214 	1,025 	18 	384 	294 	31 	830 	731 	13
Livestock 	739 	611 	21 	162 	117 	39 	577 	494 	17
Companion Animals 	475 	414 	15 	222 	177 	25 	253 	237 	7
Other Revenues (8) 188 	128 	47 	39 	46 	-15 	149 	82 	80
* 200% or greater
(4) Net product sales in Merck's marketing territories.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Total Diabetes sales were $1,353 million and $1,402 million on a global basis for first quarter 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
(3) Total Vaccines sales were $2,155 million and $1,887 million on a global basis for first quarter 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
6

-- 7 of 9 --

2020
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
TOTAL PHARMACEUTICAL 	$10,655 	$9,663 	$10,460 	$11,095 	$10,533 	$41,751 	10
United States (1) 4,714 	4,215 	4,807 	5,180 	4,751 	18,953 	12
% Pharmaceutical Sales 	44.2% 	43.6% 	46.0% 	46.7% 	45.1% 	45.4%
Europe (2) 2,543 	2,335 	2,301 	2,304 	2,373 	9,314 	9
% Pharmaceutical Sales 	23.9% 	24.2% 	22.0% 	20.8% 	22.5% 	22.3%
China 	846 	725 	745 	898 	773 	3,141 	17
% Pharmaceutical Sales 	7.9% 	7.5% 	7.1% 	8.1% 	7.3% 	7.5%
Japan 	789 	779 	900 	894 	921 	3,494 	1
% Pharmaceutical Sales 	7.4% 	8.1% 	8.6% 	8.1% 	8.7% 	8.4%
Asia Pacific (other than China and Japan) 	613 	642 	606 	638 	614 	2,500 	-4
% Pharmaceutical Sales 	5.8% 	6.6% 	5.8% 	5.8% 	5.8% 	6.0%
Eastern Europe/Middle East Africa 	490 	343 	388 	423 	423 	1,577 	43
% Pharmaceutical Sales 	4.6% 	3.6% 	3.7% 	3.8% 	4.0% 	3.8%
Latin America 	419 	427 	523 	534 	429 	1,914 	-2
% Pharmaceutical Sales 	3.9% 	4.4% 	5.0% 	4.8% 	4.1% 	4.6%
Canada 	212 	177 	179 	211 	216 	783 	20
% Pharmaceutical Sales 	2.0% 	1.8% 	1.7% 	1.9% 	2.0% 	1.9%
Other (1) 29 	20 	11 	13 	33 	75 	45
% Pharmaceutical Sales 	0.3% 	0.2% 	0.1% 	0.1% 	0.3% 	0.2%
% Change
1Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other.
(2) Europe primarily represents all European Union countries and the European Union accession markets.
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
2019
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q20 	1Q19
Interest income 	(25)	$ 	(89)	$
Interest expense 	212 	209
Exchange losses 	54 	101
(Income) loss from investments in equity securities, net (1) (52) 	25
Net periodic defined benefit plan (credit) cost other than service cost 	(90) 	(141)
Other, net 	(28) 	83
Total 	71	$ 	188	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or
through ownership interests in investment funds.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --